Vivek Vishnudas

Company: BPGBio Inc.

Job title: Chief Technology Officer

Seminars:

Novel & Differentiated Approach to Targeted Protein Degradation – Leveraging the Ubiquitin Conjugating Enzyme (E2) Family 2:15 pm

Ubiquitin Conjugating Enzymes are challenging to modulate pharmacologically using small molecules due to lack of druggable pockets Fragment Based Drug Design for the Modified (PTM) – E2 complex enabled discovery of first in class ligands Through E2 ligand extension and molecular design, efficacious bi-functional degraders have been developed for multiple proteins of interestRead more

day: Day 1, Track 2, PM